LND topic: pbms page 1

pbms

UnitedHealth's Big Steps to Fix Trust Issues

December 19, 2025

UnitedHealth Group has shared the first findings from an independent audit of its business practices. The company has promised to make changes in three key areas. They have 23 action plans in place. By the end of 2025, 65% of these plans will be done. The rest will be completed by March next year.

politics

Why Are U.S. Weight Loss Drug Prices So High?

October 7, 2024

Lawmakers have been questioning Novo Nordisk, the company behind popular weight loss drugs Ozempic and Wegovy. The Senate wants to know why these medications are priced so much higher in the U.S. compared to other countries. For example, Americans with diabetes pay $969 per month for Ozempic, while

politics

Why Are Drugs Like Ozempic and Wegovy So Expensive in the U.S.?

October 7, 2024

Imagine a world where drugs cost differently based on where you live. That's what happened at a recent Senate hearing in Washington, D.C. Novo Nordisk's CEO, Lars Fruergaard Jorgensen, was asked some tough questions about the high prices of two important medications: Ozempic for diabetes and Wegovy

business

The Insulin War: How Middlemen Hijacked Diabetes Care

September 21, 2024

In the United States, around 8 million individuals rely on insulin to manage their diabetes. However, the cost of insulin has skyrocketed over the past decade, leaving many patients unable to afford the life-saving medication. The Federal Trade Commission (FTC) has taken a bold step to address this

health

Insulin Price Fixing: The Unseen Hand Behind Diabetes

September 20, 2024

In the world of medicine, the cost of living with diabetes is skyrocketing, and it's not just because of the drugs themselves. A recent lawsuit filed by the Federal Trade Commission (FTC) against three major pharmacy benefit managers (PBMs) sheds light on a more sinister force driving up insulin pri

business

Twisting the Reins: How Pharmacy Benefit Managers Stiffed Patients on Insulin Prices

September 20, 2024

The American healthcare system has long been plagued by issues of affordability, but a recent Federal Trade Commission (FTC) lawsuit has brought attention to a particularly egregious example: pharmacy benefit managers (PBMs) allegedly inflating insulin prices at the expense of patients. The three la